Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
TXG
#1441
10x Genomics, Inc. Class A Common Stock
23.050
0
+15.37%
Sector:
Base:
Profit Currency:
Daily Range
Year Range
Daily Change
+15.37%
Monthly Change
+6.71%
6 month change
+66.79%
Year Change
+66.79%
Previous Close
19.980
0
Open
23.050
0
Bid
Ask
Low
23.050
0
High
23.050
0
Volume
221
Markets
US Stock Market
Healthcare
TXG
Open full chart
Financials
Overview
Statement
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
108.75 M
112.84 M
115.36 M
119.17 M
122.3 M
127.75 M
—
Valuation ratios
Enterprise value
14.74 B
16.22 B
3.86 B
6.11 B
1.41 B
1.61 B
4.4 B
Price to earnings ratio
—
-281.06
-24.2
-24.91
-9.45
-46.6
-88.71
Price to sales ratio
—
33.51
7.79
10.28
2.83
3.17
9.29
Price to cash flow ratio
—
769.07
119.7
418.64
259.56
14.96
102.35
Price to book ratio
—
20.11
4.99
8.59
2.44
2.56
3.89
Enterprise value to EBITDA ratio
-28.33
-521.02
-27.04
-26.59
-8.9
-64.94
-104.16
Profitability ratios
Return on assets %
0.58
0.06
0.16
0.26
0.2
0.04
0.05
Return on equity %
0.73
0.07
0.21
0.34
0.26
0.05
0.06
Return on invested capital %
1 063.42
63.67
146.96
200.22
157.93
49.62
51.56
Gross margin %
80.44
84.89
76.69
66.15
67.86
69.05
275.83
Operating margin %
178.74
10.65
32.52
42.88
31.85
9.49
39.93
EBITDA margin %
-174.05
-6.35
-27.61
-37.14
-25.98
-3.86
-18.71
Net margin %
181.61
11.87
32.15
41.23
29.9
6.77
28.78
Liquidity ratios
Quick ratio
6.3
6.23
4.23
4.11
4.26
4.09
18.06
Current ratio
6.56
6.77
4.85
4.69
4.97
4.46
20.15
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
0.39
0.5
0.5
0.62
0.65
0.66
0.66
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
0
—
—
—
—
—
—
Long term debt to total equity ratio
0
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
—
0.19
0.3
0.13
0.06
1.09
1.09
EBIT per share
—
-0.47
-1.48
-2.26
-1.62
-0.49
-0.49
EBITDA per share
—
-0.28
-1.25
-1.96
-1.32
-0.2
-0.2
Total debt per share
—
—
—
—
—
—
—
Cash per share
—
5.32
3.78
3.32
3.27
4.2
15.11
Net current asset value per share
—
6.77
5.58
5.09
4.85
5.49
20.74
Tangible book value per share
—
7.14
6.84
6.14
5.73
5.85
23.21
Working capital per share
—
5.77
4.43
4
3.88
4.26
16.55
Book value per share
—
7.41
7.08
6.32
5.9
6.38
24.62
10x Genomics Inc
10x Genomics, Inc. is an American biotechnology company that designs and manufactures sequencing technologies for use in scientific research, with a focus on product development for single-cell and spatial omics.
News
Canada stocks higher at close of trade; S&P/TSX Composite up 0.61%
Tempus AI Stock Before Q4 Earnings Release: To Buy or Not to Buy?
Priceline, Carvana, DoorDash and more set to report earnings Wednesday
10x Genomics, Inc. (TXG) Q4 2025 Earnings Call Transcript
10X Genomics stock price target raised to $22 from $20 at Canaccord Genuity
Applied Materials and Rivian among market cap stock movers on Friday
Compared to Estimates, 10x Genomics (TXG) Q4 Earnings: A Look at Key Metrics
10x Genomics (TXG) Reports Q4 Loss, Beats Revenue Estimates
10X Genomics faces earnings test as new pricing strategy debuts
Canada stocks higher at close of trade; S&P/TSX Composite up 0.71%
10x Genomics (TXG) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
UK consortium to use 10x Genomics platform for AI-driven cancer research